DuraGraft
Flushing & storage of saphenous vein grafts during CABG surgery
Key Facts
About Marizyme
Marizyme's mission is to improve long-term patient outcomes in cardiac surgery by preserving the structural and functional integrity of vascular grafts during the critical intraoperative period. Its primary achievement is the FDA clearance and commercialization of DuraGraft®, the first and only solution specifically cleared for flushing and storing saphenous vein grafts in CABG, supported by clinical data demonstrating reduced graft wall thickening. The company's strategy is centered on penetrating the global CABG market with DuraGraft while exploring potential platform extensions into other vascular storage applications. Marizyme operates as a public company, focusing its resources on driving surgeon adoption and securing reimbursement pathways for its novel technology.
View full company profile